Clinical Trials Using DNA-PK/TOR Kinase Inhibitor CC-115

Clinical trials are research studies that involve people. The clinical trials on this list are studying DNA-PK/TOR Kinase Inhibitor CC-115. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-2 of 2
  • Abemaciclib, DNA-PK / TOR Kinase Inhibitor CC-115, or Neratinib in Treating Patients with Brain Tumors after Biomarker Screening

    This randomized phase II trial studies how well abemaciclib, DNA-PK / TOR kinase inhibitor CC-115, or neratinib works in treating patients with brain tumors after biomarker screening. Drugs such as abemaciclib, DNA-PK / TOR kinase inhibitor CC-115, or neratinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Screening tumor samples for biomarkers may help doctors to determine if certain treatments work better on patients with certain biomarkers. Giving abemaciclib, DNA-PK / TOR kinase inhibitor CC-115, or neratinib may work better in treating patients with brain tumors.
    Location: 12 locations

  • Enzalutamide and DNA-PK / TOR Kinase Inhibitor CC-115 in Treating Patients with Metastatic Castration-Resistant Prostate Cancer

    This phase Ib trial studies the side effects and best dose of deoxyribonucleic acid-dependent protein kinase (DNA-PK) / target of rapamycin (TOR) kinase inhibitor CC-115 when given together with enzalutamide in treating patients with castration-resistant prostate cancer that has spread to other places in the body. DNA-PK / TOR kinase inhibitor CC-115 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Enzalutamide is an androgen receptor inhibitor that may slow down the growth of prostate cancer by blocking the action of the male hormone testosterone and other male hormones called androgens. Giving DNA-PK / TOR kinase inhibitor CC-115 and enzalutamide may work better in treating patients with castration-resistant prostate cancer.
    Location: 4 locations